Open AccessCamptothecin enhances 131I-rituximab-induced G1-arrest and apoptosis in Burkitt lymphoma cells
Author(s) -
Chandan Kumar,
Rohit Sharma,
Krishna Mohan Repaka,
Aanchal Udaynath Pareri,
Ashutosh Dash
Publication year - 2021
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_1012_19
Subject(s) - rituximab , camptothecin , raji cell , apoptosis , cancer research , cd20 , monoclonal antibody , programmed cell death , chemistry , medicine , lymphoma , pharmacology , antibody , immunology , biochemistry
Rituximab is a chimeric monoclonal antibody against CD20. It is an established immunotherapeutic agent for non-Hodgkin's lymphoma. Even though rituximab has been used in clinics for decades, only 50% of the patients respond to rituximab therapy. To enhance the in vitro effect of rituximab, it was labeled with Iodine-131 ( 131 I) and combined effect of 131 I-rituximab and camptothecin (CPT) was studied on a tumor cell line expressing CD20.